Connect with us

Eyecare

Biotech Firm Receives $7.5M Grant for Glaucoma Research

The money comes from the German state of Saxony.

mm

Published

on

NEW YORK — Q BioMed Inc., a commercial stage biotech company, announced that its technology partner, Mannin, has received a $7.5M grant from the German state of Saxony.

The objective of the grant is to fund the development of novel pharmaceuticals and biologic treatments for glaucoma.

Eyecare Shenanigans: 2023’s Top Optometry Articles in Invision Magazine
Eyecare Shenanigans

Eyecare Shenanigans: 2023’s Top Optometry Articles in Invision Magazine

Bringing Independent ECPs Into the 21st Century With the Technology Solutions a Modern Eyecare Business Needs
INVISION Podcast

Bringing Independent ECPs Into the 21st Century With the Technology Solutions a Modern Eyecare Business Needs

The Making of Bespoke Eyewear, An Acetate Kitchen and Collecting Famous People’s Heads
INVISION Podcast

The Making of Bespoke Eyewear, An Acetate Kitchen and Collecting Famous People’s Heads

The approval of the grant means that Q BioMed and Mannin “can significantly accelerate the development of these therapeutics,” according to a press release.

Denis Corin, CEO of Q BioMed, said, “We are thrilled that we will be able to speed the development of these promising therapeutics and bring new innovation to glaucoma patients as soon as possible. Our partnership with Mannin and now, the government of Saxony is important to the advancement of this unique drug platform and we look forward to supporting the build-out of the Mannin European headquarters in Leipzig.”

Mannin is a research-stage biotechnology company focused on the discovery, development and commercialization of therapeutics for vascular diseases. It was founded in July 2012 and is led by President and CEO Dr. George Nikopoulos. Q BioMed and Mannin have been partners since 2015.

Advertisement

George Nikopoulos, president and CEO of Mannin, stated, “We are very encouraged by the confidence and enthusiasm the government of Saxony has shown in our research, and we are committed to making accelerated progress through their investment.”

Mannin is leveraging two distinct modes of action to reduce the intraocular pressure that causes glaucoma, utilizing different routes of administration and dosing regimens. Mannin is currently working on the preclinical development of a small molecule pharmaceutical eye-drop as well as a novel recombinant protein injectable biologic. This approach “increases the probability of success of developing a new therapy that is optimized for the needs of glaucoma patients,” according to the release. Additionally, Mannin is exploring other therapeutic opportunities using these molecules for vascular diseases.

Q BioMed and Mannin intend to announce further details regarding the research program later this year.

SPONSORED VIDEO

Meet the Next Generation of Smart Glasses

Ray-Ban Meta is now available with a full range of lenses, as a complete pair or edged lens. Prescription orders eligible through select insurance providers, including Eyemed and private pay. The Ray-Ban Meta collection combines iconic design with cutting-edge technology. Capture life’s best moments and livestream to Facebook and Instagram with an upgraded 12 MP camera and five-mic system. Stay connected with hands-free calls and messages. Listen to your favorite tracks through built-in speakers. Spark your creativity, get information and control your glasses with your voice – powered by Meta AI. All while keeping your phone in your pocket. For more information, visit here.

Promoted Headlines

Most Popular